Antibiotic Falls Short in Disc-Related Back Pain - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.

  • By

  • Kathryn Wighton

  • May 28, 2026

  • 5 min

Share

Objective:

To assess the efficacy of amoxicillin-clavulanate in reducing pain among patients with chronic low back pain and disc herniation compared to placebo.

Key Findings:
  • At 12 months, mean pain reduction was 1.0 point for amoxicillin-clavulanate vs 1.1 points for placebo, with no significant difference.
  • No differences in disability, work absence, or psychological measures were observed between groups at 12 months.
  • Subgroup analyses did not show pain benefit among patients with Modic changes.
Interpretation:

The findings indicate that amoxicillin-clavulanate did not show a significant difference in pain relief compared to placebo.

Limitations:
  • The trial was not primarily powered to test efficacy in patients with Modic changes.
  • Generalizability may be limited as most patients were recruited from the community.
  • Missing data for 18 patients and discontinuation of antimicrobial resistance sampling.
Conclusion:

The results indicate uncertainty regarding the efficacy of antibiotics for chronic low back pain with disc herniation.

Original Source(s)

Antibiotic Falls Short in Disc-Related Back Pain

  • by Kathryn Wighton

  • May 28, 2026

Related Content

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.

Self-Management May Reduce Chronic Low Back Pain

In a randomized clinical trial of patients at increased risk for persistent symptoms, clinician-supported biopsychosocial self-management was associated with lower pain impact and fewer chronic pain outcomes than guideline-based medical care.

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.